Curious about the science behind LSD microdosing and its potential to transform mental health? Few substances have sparked as much scientific and cultural fascination as LSD, from its discovery in 1938 to its influence on psychiatry, music, and art before research was halted by prohibition. Today, Dr. Suresh Muthukumaraswamy and Dr. Rachael Sumner at the University of Auckland are leading the world’s first government-sanctioned clinical trials on LSD microdosing for mood disorders, providing rigorous evidence on its effects on mood, cognition, sleep, and mental health. Join Microdosing Collective and Third Wave for a live webinar to explore their pioneering research, the neuroscience of microdosing, and what this means for the future of mental health treatments. This session includes key findings, clinical insights, and a live Q&A with the researchers, alongside featured hosts Stephanie Karzon Abrams and Paul F. Austin.
Neuropharmacologist and Lead Researcher at the University of Auckland
Clinical Researcher at the University of Auckland
Research Director at Microdosing Collective
Co-Founder and Educational Director of Microdosing Collective, Founder of Third Wave and the Psychedelic Coaching Institute.
Subscribe to THE DOSE and get the latest microdosing news, expert insights, legalization updates, and exclusive events—delivered straight to your inbox! 📩
